When combining triptans with SSRIs/SNRIs or MAO inhibitors, what syndrome is of concern?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

When combining triptans with SSRIs/SNRIs or MAO inhibitors, what syndrome is of concern?

When several serotonergic drugs are used together, the risk of serotonin syndrome increases. Triptans have serotonergic activity, and SSRIs/SNRIs raise serotonin by blocking its reuptake, while MAO inhibitors prevent serotonin breakdown. Together, they can produce excessive serotonin in the CNS, leading to serotonin syndrome. This condition presents with a rapid onset of mental status changes (e.g., agitation, confusion), autonomic instability (fever, sweating, tachycardia, hypertension), and neuromuscular findings (tremor, myoclonus, hyperreflexia, possibly clonus). It can be serious and requires stopping the offending agents and providing supportive care; in more significant cases, a serotonin antagonist like cyproheptadine may be used, along with cooling and careful monitoring. Other options don’t fit the scenario: rhabdomyolysis can occur as a complication but is not the syndrome defined by this drug interaction; neuroleptic malignant syndrome is due to dopamine blockade (often from antipsychotics) and has a different clinical pattern; malignant hyperthermia is a reaction to certain anesthetics and is not driven by serotonergic drug interactions.

When several serotonergic drugs are used together, the risk of serotonin syndrome increases. Triptans have serotonergic activity, and SSRIs/SNRIs raise serotonin by blocking its reuptake, while MAO inhibitors prevent serotonin breakdown. Together, they can produce excessive serotonin in the CNS, leading to serotonin syndrome.

This condition presents with a rapid onset of mental status changes (e.g., agitation, confusion), autonomic instability (fever, sweating, tachycardia, hypertension), and neuromuscular findings (tremor, myoclonus, hyperreflexia, possibly clonus). It can be serious and requires stopping the offending agents and providing supportive care; in more significant cases, a serotonin antagonist like cyproheptadine may be used, along with cooling and careful monitoring.

Other options don’t fit the scenario: rhabdomyolysis can occur as a complication but is not the syndrome defined by this drug interaction; neuroleptic malignant syndrome is due to dopamine blockade (often from antipsychotics) and has a different clinical pattern; malignant hyperthermia is a reaction to certain anesthetics and is not driven by serotonergic drug interactions.

More practice questions